Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for ...(single- and multiple-dose Phase 1 studie...)

Date:1/12/2009

single- and multiple-dose Phase 1 studies in humans and has demonstrated efficacy in heart failure in several open-label Phase 2 trials. To date approximately 1,000 patients have received alagebrium treatment and the drug continues to exhibit a clean safety profile.

About Heart Failure

Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. The primary manifestations of heart failure are dyspnea and fatigue, which may limit exercise tolerance, result in fluid retention, and lead to pulmonary congestion and peripheral edema. These abnormalities impair the functional capacity and quality of life of affected individuals.

Heart failure is a major and growing global public health problem. Approximately 5 million patients in the U.S. and about 10 million in Europe have heart failure, according to the American Heart Association. The number of heart failure deaths has increased steadily despite advances in treatment. Heart failure results in more than 1 million hospitalizations at a cost of more than $15 billion annually in the U.S. alone.

Most of the available treatments for heart failure are not aimed at the underlying pathophysiological processes that occur in the heart itself. In this respect, the Company believes that accumulation of A.G.E.s might prove to be a promising, novel target for the treatment of heart failure. A.G.E.s are proteins formed by oxidative or non-oxidative reactions. A.G.E.s cause the formation of collagen cross-links, which result in increased myocardial stiffness whereby the stiff ventricle fails to relax adequately between beats and to allow blood to fill the chamber. As a result, blood backs up into the lungs and makes patients short of breath. More than 50% of patients with symptoms of heart failure have evidence of a stiff non-compliant ventricle (hear
'/>"/>

SOURCE Synvista Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association